Copiktra HCP
COPIKTRA for CLL/SLL
Efficacy
Safety
MOA
Dosing & AR Management
Support & Resources
REMS
Patient Site
Efficacy – PFS Tab 1
More than 60% of patients were progression free after 1 year on COPIKTRA
3